(Q46165734)

English

The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection

scientific article published on 22 December 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

Mycobacterium tuberculosis

0 references

1 reference

based on heuristic

inferred from title

author name string

Yi-Ming Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

Hsin-Hua Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

Kuo-Lung Lai

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

Wei-Ting Hung

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

Joung-Liang Lan

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

Der-Yuan Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

publication date

22 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

52

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

697-704

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

TNF-blocking agents and tuberculosis: new drugs illuminate an old topic

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Communication between Dutch rheumatologists and occupational physicians in the occupational rehabilitation of patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

IL-17 and IFN-γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

B cell non-Hodgkin's lymphoma: rituximab safety experience

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Mycobacterium tuberculosis in Taiwan

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

The prognosis of latent tuberculosis: can disease be predicted?

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKES365

21 January 2018

Identifiers

10.1093/RHEUMATOLOGY/KES365

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/23264552

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46165734&oldid=2096412326"